Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025
Ascendis Pharma (Nasdaq: ASND) has announced it will release its full year 2024 financial results and provide a business update on Wednesday, February 12, 2025, after U.S. market close. The company will host a conference call and live webcast at 4:30 p.m. Eastern Time on the same day to discuss the results. Interested participants can access the webcast directly or register for the teleconference in advance. The webcast will be available for replay on the company's investor relations website for 30 days following the event.
Ascendis Pharma (Nasdaq: ASND) ha annunciato che rilascerà i suoi risultati finanziari completi per l'anno 2024 e fornirà un aggiornamento aziendale il mercoledì 12 febbraio 2025, dopo la chiusura del mercato statunitense. L'azienda ospiterà una conferenza telefonica e un webcast dal vivo alle 4:30 p.m. Eastern Time nello stesso giorno per discutere i risultati. I partecipanti interessati possono accedere direttamente al webcast o registrarsi in anticipo per la teleconferenza. Il webcast sarà disponibile per la replica sul sito web delle relazioni con gli investitori dell'azienda per 30 giorni dopo l'evento.
Ascendis Pharma (Nasdaq: ASND) ha anunciado que publicará sus resultados financieros completos para el año 2024 y proporcionará una actualización empresarial el miércoles 12 de febrero de 2025, después del cierre del mercado estadounidense. La compañía llevará a cabo una llamada de conferencia y un webcast en vivo a las 4:30 p.m. hora del este el mismo día para discutir los resultados. Los participantes interesados pueden acceder al webcast directamente o registrarse previamente para la teleconferencia. El webcast estará disponible para su repetición en el sitio web de relaciones con inversores de la compañía durante 30 días después del evento.
Ascendis Pharma (Nasdaq: ASND)는 2024 회계연도 전체 재무 결과를 발표하고 2025년 2월 12일 수요일에 미국 시장 마감 후 비즈니스 업데이트를 제공할 것이라고 발표했습니다. 회사는 같은 날 동부 표준시 오후 4시 30분에 결과에 대해 논의하기 위해 컨퍼런스 콜 및 실시간 웹캐스트를 개최할 것입니다. 관심 있는 참가자는 웹캐스트에 직접 접속하거나 사전에 전화회의에 등록할 수 있습니다. 웹캐스트는 이벤트 이후 30일 동안 회사의 투자자 관계 웹사이트에서 재생할 수 있습니다.
Ascendis Pharma (Nasdaq: ASND) a annoncé qu’il publiera ses résultats financiers complets pour l’année 2024 et fournira une mise à jour sur l’entreprise le mercredi 12 février 2025, après la fermeture des marchés américains. La société organisera une conférence téléphonique et un webinaire en direct le même jour à 16h30, heure de l'Est, pour discuter des résultats. Les participants intéressés peuvent accéder directement au webinaire ou s'inscrire à l'avance pour la téléconférence. Le webinaire sera disponible en replay sur le site web des relations investisseurs de la société pendant 30 jours suivant l'événement.
Ascendis Pharma (Nasdaq: ASND) hat bekannt gegeben, dass das Unternehmen am Mittwoch, den 12. Februar 2025, nach Börsenschluss in den USA seine vollständigen Finanzzahlen für das Jahr 2024 veröffentlichen und ein Update zum Geschäft geben wird. Am selben Tag um 16:30 Uhr Eastern Time wird das Unternehmen eine Telefonkonferenz und ein Live-Webcast zur Diskussion der Ergebnisse abhalten. Interessierte Teilnehmer können entweder direkt auf den Webcast zugreifen oder sich im Voraus für die Telefonkonferenz anmelden. Der Webcast wird für 30 Tage nach der Veranstaltung auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
COPENHAGEN, Denmark, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report full year 2024 financial results and provide a business update on Wednesday, February 12, 2025, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on February 12, 2025, at 4:30 p.m. Eastern Time (ET) to discuss 2024 financial results.
Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma.com. A replay of the webcast will be available on this section of the Ascendis Pharma website shortly after conclusion of the event for 30 days.
About Ascendis Pharma A/S
Ascendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of Patients, Science, and Passion, Ascendis uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ ability to apply its TransCon technology platform to build a leading, fully integrated biopharma company and (ii) Ascendis’ use of its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis’ products and product candidates; unforeseen safety or efficacy results in Ascendis’ development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis’ development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis’ business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ prospectus supplement filed on September 20, 2024 and Ascendis’ current and future reports filed with, or submitted to, the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 20-F filed with the SEC on February 7, 2024. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, SKYTROFA®, and YORVIPATH® are trademarks owned by the Ascendis Pharma group.
© February 2025 Ascendis Pharma A/S.
| Investor Contacts: | Media Contact: |
| Scott Smith | Melinda Baker |
| Ascendis Pharma | Ascendis Pharma |
| ir@ascendispharma.com | +1 (650) 709-8875 |
| media@ascendispharma.com | |
| Patti Bank | |
| ICR Healthcare | |
| +1 (415) 513-1284 | |
| patti.bank@icrhealthcare.com |
FAQ
When will Ascendis Pharma (ASND) release its full year 2024 financial results?
What time is Ascendis Pharma's (ASND) earnings call for full year 2024 results?
How long will Ascendis Pharma's (ASND) Q4 2024 earnings webcast be available for replay?
Where can I access Ascendis Pharma's (ASND) 2024 full year earnings webcast?
